# Daiichi Sankyo Begins Phase 1 Testing of Under-the-Skin Enhertu With Alteogen's Enzyme

Soon Jae Park's enzyme technology opened a new formulation project for Daiichi Sankyo's cancer medicine. The partner began its patient study in July 2025 and is investigating which subcutaneous dose can support further development.

Canonical: https://kgcf.dsmlholdings.com/insights/alteogen-enhertu-clinical-progression/
Published: 2026-10-08
Modified: 2026-10-31
Author: [DSML Holdings LLC](https://www.dsmlholdings.com/)

Company: Alteogen
Event: 2025-06-13
Alteogen reported preparations for patient enrolment after US investigational-drug clearance on 13 June 2025; the study began on 17 July.

## Reported Metrics

- Reported clinical stage: Phase 1. Alteogen's 13 June 2025 enrolment preparations; the sponsor records an actual start on 17 July 2025. [Source 1](https://alteogen.com/en/sub/ir/information.php?bid=14&idx=157&mode=view)

- Referenced licence payment ceiling: USD 300m. Up to USD300 million in licence payments stated on 13 June 2025; royalties are additional. [Source 1](https://alteogen.com/en/sub/ir/information.php?bid=14&idx=157&mode=view)

Daiichi Sankyo began a Phase 1 study of subcutaneous trastuzumab deruxtecan on 17 July 2025, following Alteogen's June account of enrolment preparations after US investigational-drug clearance. The project uses Alteogen's ALT-B4 enzyme. Its July 2026 update describes an ongoing dose-escalation and expansion programme with seventy-six participants planned.

Park's Alteogen supplied an enabling enzyme; Daiichi Sankyo organised the investigation of a new formulation of its antibody-drug conjugate. The partnership moved from a proposed alternative to intravenous delivery into a patient study. The development work now centres on choosing a dose and understanding drug exposure and tolerability, the practical steps needed before a subcutaneous ADC can advance.

The agreement combines technology access with Alteogen's responsibility for clinical and eventual commercial enzyme supply. It carries up to USD300 million in licence payments, excluding royalties, with development, regulatory and sales milestones. Its longer-term business lies in supporting this particular medicine as the drug owner takes it through development.

## Park Put Alteogen's Enzyme Inside a Different Kind of Oncology Programme

Alteogen's November 2024 announcement granted Daiichi Sankyo worldwide rights to use ALT-B4 for a subcutaneous version of Enhertu. The underlying medicine, trastuzumab deruxtecan, is a HER2-directed antibody-drug conjugate jointly developed and commercialised by Daiichi Sankyo and AstraZeneca. The licence concerned an alternative formulation of that medicine, not ownership of the partners' therapeutic franchise.

Chief executive Soon Jae Park presented applying hyaluronidase to an ADC as a significant new collaboration for Alteogen. Its Hybrozyme platform produces ALT-B4, a recombinant human enzyme that temporarily breaks down hyaluronan in the extracellular matrix, enabling larger-volume medicines to be delivered beneath the skin. That is the mechanism the company proposed to bring to Enhertu development. The agreement also assigned Alteogen the clinical and commercial supply of ALT-B4. Park's team would therefore contribute manufactured enzyme as well as formulation know-how. The collaboration connected a Korean component developer with the organisation responsible for Enhertu, giving that team a new kind of oncology project to supply and support.

4. [Alteogen / original Daiichi Sankyo worldwide licence and clinical-commercial supply role](https://alteogen.com/en/sub/ir/news.php?bid=13&idx=148&mode=view&page=1)

## Daiichi Sankyo Moved From Enrolment Preparations to a Patient Study

By June 2025, Daiichi Sankyo had received US investigational-drug clearance and was preparing patient enrolment. Alteogen described those preparations on 13 June, shortly after the study's public registration. The actual study began on 17 July, according to the sponsor's subsequent update.

Daiichi Sankyo sponsors the programme, with AstraZeneca listed as collaborator. The partners are testing subcutaneous trastuzumab deruxtecan in people with metastatic solid tumours through an open-label, non-randomised Phase 1 design. By the July 2026 update, the trial was recruiting across sites in the United States, Japan, South Korea, Taiwan, France and Spain.

The international programme takes the formulation into the kinds of oncology services where the drug would have to work in practice. Sites in Brazil were also listed but had not yet begun recruiting. The sponsor plans seventy-six participants across dose escalation and expansion, organising a relatively small early study around a specific formulation decision.

1. [Alteogen / Phase 1 business update](https://alteogen.com/en/sub/ir/information.php?bid=14&idx=157&mode=view)
2. [Daiichi Sankyo / sponsor trial registry, latest posted update](https://clinicaltrials.gov/study/NCT07015697)

## The First Part Selects the Dose for the Second

The first group receives increasing subcutaneous doses. Daiichi Sankyo will use those observations to choose a recommended dose for the expansion group. Investigators monitor treatment-emergent adverse events, dose-limiting toxicities and drug exposure measured over time. Anti-drug antibodies and tumour responses provide additional information.

Eligibility reflects the medicine's particular development setting. The study includes previously treated HER2-positive breast cancer, defined HER2-low or ultralow breast-cancer populations, and HER2-mutated non-small cell lung cancer. Prior treatment requirements differ between these groups. This is not a general trial of quicker injections for every person with cancer.

Patients with relevant lung inflammation or fibrosis histories and specified cardiac risks are excluded. These safeguards matter when changing delivery of a potent ADC: administering it beneath the skin still requires an acceptable systemic exposure and safety profile. The sponsor estimates completion in December 2028; its July 2026 update contains no results.

2. [Daiichi Sankyo / sponsor trial registry, latest posted update](https://clinicaltrials.gov/study/NCT07015697)

## Merck Gained Approval for a Separate Enzyme Programme

While the Enhertu study was under way, another Alteogen-enabled formulation reached US approval. On 19 September 2025, Merck announced Keytruda Qlex and identified Alteogen as the developer and manufacturer of its hyaluronidase component. That was an approved application of the Korean company's enzyme work, alongside the earlier-stage ADC investigation.

In Merck's announcement, oncologist J. Thaddeus Beck described what the separate pembrolizumab formulation changed for his profession: shorter administration and a choice of treatment settings. He referred to the approved Qlex schedules and its comparison with intravenous pembrolizumab. His account explains why cancer-drug developers are interested in another administration route, but those Qlex results do not establish the clinical profile of subcutaneous Enhertu.

Park's November licence had proposed taking hyaluronidase into the ADC field. Daiichi Sankyo's July start put that proposal into an active development programme. Alteogen now has two distinct operating roles around that work: supplying the enzyme used in investigation and contributing technology for a potential future formulation. The dose selected by this study will shape what the partners can do next.

3. [Merck / approved formulation and Alteogen's component-supply role](https://www.merck.com/news/fda-approves-mercks-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-injection-for-subcutaneous-use-in-adults-across-most-solid-tumor-indications-for-keytruda-pem/)
5. [Merck / archived original Qlex approval notice identifying Alteogen's supplied enzyme](https://s2.q4cdn.com/584635680/files/doc_news/FDA-Approves-Mercks-KEYTRUDA-QLEX-pembrolizumab-and-berahyaluronidase-alfa-pmph-Injection-for-Subcutaneous-Use-in-Adults-Across-Most--3OOHA.pdf)
4. [Alteogen / original Daiichi Sankyo worldwide licence and clinical-commercial supply role](https://alteogen.com/en/sub/ir/news.php?bid=13&idx=148&mode=view&page=1)
2. [Daiichi Sankyo / sponsor trial registry, latest posted update](https://clinicaltrials.gov/study/NCT07015697)

Subcutaneous Enhertu remains investigational. Its next development step depends on the dose, exposure and tolerability of this ADC formulation, rather than the approval of a different enzyme-containing cancer medicine.


### Primary Sources

1. [Alteogen / Phase 1 business update](https://alteogen.com/en/sub/ir/information.php?bid=14&idx=157&mode=view) (2025-06-13)

2. [Daiichi Sankyo / sponsor trial registry, latest posted update](https://clinicaltrials.gov/study/NCT07015697) (2026-07-09)

3. [Merck / approved formulation and Alteogen's component-supply role](https://www.merck.com/news/fda-approves-mercks-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-injection-for-subcutaneous-use-in-adults-across-most-solid-tumor-indications-for-keytruda-pem/) (2025-09-19)

4. [Alteogen / original Daiichi Sankyo worldwide licence and clinical-commercial supply role](https://alteogen.com/en/sub/ir/news.php?bid=13&idx=148&mode=view&page=1) (2024-11-14)

5. [Merck / archived original Qlex approval notice identifying Alteogen's supplied enzyme](https://s2.q4cdn.com/584635680/files/doc_news/FDA-Approves-Mercks-KEYTRUDA-QLEX-pembrolizumab-and-berahyaluronidase-alfa-pmph-Injection-for-Subcutaneous-Use-in-Adults-Across-Most--3OOHA.pdf) (2025-09-19)
